Cara Therapeutics Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Los beneficios de Cara Therapeutics han disminuido a una tasa media anual de -4%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 1.7% anualmente. Los ingresos han ido creciendo a una tasa media de 4.5% al año.
Información clave
-6.9%
Tasa de crecimiento de los beneficios
1.5%
Tasa de crecimiento del BPA
Crecimiento de la industria Pharmaceuticals | 6.0% |
Tasa de crecimiento de los ingresos | -2.9% |
Rentabilidad financiera | -411.2% |
Margen neto | -723.5% |
Última actualización de beneficios | 31 Mar 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope
May 29Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S
May 25We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Feb 16The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%
Dec 19News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts
Nov 04Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?
Oct 25Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?
Jul 20Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper
Jun 04News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat
Mar 11Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates
Feb 15We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth
Feb 06We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow
Oct 18Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients
Sep 28Cara Therapeutics hires new finance chief
Sep 12Cara Therapeutics: All Eyes On Korsuva Launch Metrics
Sep 01Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients
Aug 19Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M
Aug 08Calls A Much Safer Way To Buy Cara Therapeutics
Jun 24We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Jun 15Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts
May 12Taking A (Speculative) Position In Cara Therapeutics
Mar 21Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth
Mar 09Cara Therapeutics: De-Risked And Extremely Attractive
Dec 25Checking Back In On Cara Therapeutics
Nov 01Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA
Aug 21The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically
Aug 15Cara Therapeutics: 200% Upside Possible With FDA Approval
Aug 11Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive
Jul 19It's Unlikely That The CEO Of Cara Therapeutics, Inc. (NASDAQ:CARA) Will See A Huge Pay Rise This Year
May 28Desglose de ingresos y gastos
Cómo gana y gasta dinero Cara Therapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
31 Mar 24 | 17 | -123 | 29 | 0 |
31 Dec 23 | 21 | -119 | 29 | 0 |
30 Sep 23 | 21 | -117 | 29 | 0 |
30 Jun 23 | 27 | -112 | 29 | 0 |
31 Mar 23 | 43 | -84 | 29 | 0 |
31 Dec 22 | 42 | -85 | 31 | 0 |
30 Sep 22 | 39 | -89 | 36 | 0 |
30 Jun 22 | 49 | -66 | 35 | 0 |
31 Mar 22 | 26 | -93 | 34 | 0 |
31 Dec 21 | 23 | -88 | 31 | 0 |
30 Sep 21 | 134 | 24 | 25 | -6 |
30 Jun 21 | 123 | 8 | 25 | 0 |
31 Mar 21 | 129 | 14 | 24 | 0 |
31 Dec 20 | 135 | 8 | 23 | 0 |
30 Sep 20 | 28 | -99 | 20 | 6 |
30 Jun 20 | 24 | -115 | 19 | 0 |
31 Mar 20 | 24 | -113 | 18 | 0 |
31 Dec 19 | 20 | -106 | 18 | 0 |
30 Sep 19 | 21 | -98 | 18 | 0 |
30 Jun 19 | 20 | -85 | 17 | 0 |
31 Mar 19 | 18 | -79 | 16 | 0 |
31 Dec 18 | 13 | -74 | 15 | 0 |
30 Sep 18 | 8 | -68 | 14 | 0 |
30 Jun 18 | 3 | -61 | 14 | 0 |
31 Mar 18 | 0 | -53 | 13 | 0 |
31 Dec 17 | 1 | -58 | 12 | 0 |
30 Sep 17 | 1 | -66 | 11 | 0 |
30 Jun 17 | 1 | -65 | 9 | 0 |
31 Mar 17 | 1 | -69 | 9 | 0 |
31 Dec 16 | 0 | -57 | 9 | 0 |
30 Sep 16 | 0 | -45 | 9 | 0 |
30 Jun 16 | 3 | -38 | 9 | 0 |
31 Mar 16 | 3 | -31 | 8 | 0 |
31 Dec 15 | 4 | -25 | 8 | 0 |
30 Sep 15 | 5 | -19 | 7 | 0 |
30 Jun 15 | 3 | -21 | 7 | 0 |
31 Mar 15 | 3 | -19 | 7 | 0 |
31 Dec 14 | 3 | -18 | 6 | 0 |
30 Sep 14 | 3 | -16 | 5 | 1 |
30 Jun 14 | 3 | -14 | 5 | 2 |
31 Mar 14 | 12 | -6 | 4 | 3 |
31 Dec 13 | 12 | -3 | 4 | 0 |
30 Sep 13 | 11 | -3 | 3 | 3 |
30 Jun 13 | 11 | 1 | 3 | 4 |
Ingresos de calidad: CARA actualmente no es rentable.
Margen de beneficios creciente: CARA actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: CARA no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 4% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CARA en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: CARA no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (-6.8%).
Rentabilidad financiera
Alta ROE: CARA tiene una rentabilidad financiera negativa (-207.61%), ya que actualmente no es rentable.